Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
August 7, 2018 6:34 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.36), versus ($1.89) reported last year.
Conditional acceptance granted by U.S. Food and Drug Administration (FDA) for the proprietary name ZULRESSO for Sages intravenous formulation of brexanolone
Continuing to execute commercial build and launch readiness for ZULRESSO (brexanolone injection) in postpartum depression ahead of PDUFA target date of December 19, 2018
Accelerating... More
Piper Jaffray Starts Sage Therapeutics (SAGE ) at Overweight
August 6, 2018 5:34 AM EDTPiper Jaffray initiates coverage on Sage Therapeutics (NASDAQ: SAGE ) with a Overweight rating and a price target of $206.00.
Analyst Danielle Brill believes the company is attractive citing robust supportive data generated in 2018, the novel approach to threat of CNS disorders, the pipeline depth, and consistent management... More
